Gregory A. Tannock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gregory A. Tannock has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Jianming Tan
Department of Biotechnology and Environmental Biology, School of Applied Sciences, RMIT University, Bundoora, Victoria 3083, Australia
2 shared publicationsJulie Cooke
Department of Biotechnology and Environmental Biology, School of Applied Sciences, RMIT university, P.O. Box 71, Bundoora, Victoria 3083, Australia
2 shared publicationsNadeene Clarke
Department of Biotechnology and Environmental Biology, School of Applied Sciences, RMIT university, P.O. Box 71, Bundoora, Victoria 3083, Australia
2 shared publicationsG.A Marsh
Department of Biotechnology and Environmental Biology, RMIT University, PO Box 71, Bundoora, Vic 3083, Australia
1 shared publicationJ M Audsley
RMIT University, Department of Biotechnology and Environmental Biology, PO Box 71, Bundoora Vic., 3083, Australia
1 shared publicationJ.M Watson
Department of Biotechnology and Environmental Biology, RMIT University, PO Box 71, Bundoora, Vic. 3083, Australia
1 shared publication
Latest Publications
- 29 February 2008
- Published by Elsevier in Journal of Virological Methods
- Vol. 147 (2) , 312-318
Optimization of methods for the isolation of Marek's disease viruses in primary chicken cell cultures
- 29 February 2008
- Published by Elsevier in Journal of Virological Methods
- Vol. 147 (2) , 312-318
Optimization of methods for the isolation of Marek's disease viruses in primary chicken cell cultures
- Open Access
- 1 October 2007
- Published by Taylor & Francis in Avian Pathology
- Vol. 36 (5) , 351-359
Molecular evaluation of responses to vaccination and challenge by Marek's disease viruses
A real-time quantitative polymerase chain reaction was utilized to study the in vivo replication of Marek's disease vaccine viruses and of virulent oncogenic strains. In the first of four experiments, the growth of the herpes virus of turkeys (HVT) vaccine was detectable in various organs of infected chicken embryos, with the highest viral loads being present in the spleen. No evidence was obtained for replication of serotype-1 Marek's disease viruses in embryos. In the second experiment, viral loads were measured in several organs of chickens after administration of the Rispens and HVT vaccines immediately after hatching. Lowest levels were noted for the Rispens strain after 1 to 8 weeks. By contrast, HVT vaccine grew well in all tested organs, with the highest loads being present in the spleen. Highest loads were observed in unvaccinated birds after challenge with the highly virulent strain MPF57 at day 8, especially in lymphoid organs. A positive relationship was observed between viral load and clinical signs, including tumour formation. In a third study, viral loads were measured in the organs of chickens administered the Rispens vaccine on the day of hatch and challenged at day 8 with MPF57. High levels of clinical protection were afforded against MPF57 by the Rispens vaccine but, in confirmation of earlier findings, sterilizing immunity was not induced. In a fourth study, two experiments were conducted—in which viral loads were measured after challenge of chickens vaccinated with HVT in ovo or at day 1 after hatching. Similar protection was achieved in birds vaccinated in ovo on embryonic days 11 and 17, although protection was slightly, but not significantly, lower than for birds vaccinated at day 1.
- 1 October 2007
- Published by Taylor & Francis in Avian Pathology
- Vol. 36 (5) , 351-359
Open AccessMolecular evaluation of responses to vaccination and challenge by Marek's disease viruses
A real-time quantitative polymerase chain reaction was utilized to study the in vivo replication of Marek's disease vaccine viruses and of virulent oncogenic strains. In the first of four experiments, the growth of the herpes virus of turkeys (HVT) vaccine was detectable in various organs of infected chicken embryos, with the highest viral loads being present in the spleen. No evidence was obtained for replication of serotype-1 Marek's disease viruses in embryos. In the second experiment, viral loads were measured in several organs of chickens after administration of the Rispens and HVT vaccines immediately after hatching. Lowest levels were noted for the Rispens strain after 1 to 8 weeks. By contrast, HVT vaccine grew well in all tested organs, with the highest loads being present in the spleen. Highest loads were observed in unvaccinated birds after challenge with the highly virulent strain MPF57 at day 8, especially in lymphoid organs. A positive relationship was observed between viral load and clinical signs, including tumour formation. In a third study, viral loads were measured in the organs of chickens administered the Rispens vaccine on the day of hatch and challenged at day 8 with MPF57. High levels of clinical protection were afforded against MPF57 by the Rispens vaccine but, in confirmation of earlier findings, sterilizing immunity was not induced. In a fourth study, two experiments were conducted—in which viral loads were measured after challenge of chickens vaccinated with HVT in ovo or at day 1 after hatching. Similar protection was achieved in birds vaccinated in ovo on embryonic days 11 and 17, although protection was slightly, but not significantly, lower than for birds vaccinated at day 1.
- 1 October 2004
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 2 (5) , 663-666
The changing face of virology: will the application of molecular techniques inevitably lead to new and better vaccines?
- 1 October 2004
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 2 (5) , 663-666
The changing face of virology: will the application of molecular techniques inevitably lead to new and better vaccines?
- 1 January 2004
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 4 (5) , 709-717
The role of cell culture vaccines in the control of the next influenza pandemic
Pandemic influenza A viruses of avian origin are of particular concern and have crossed the species barrier several times in recent years, giving rise to illness and occasionally death in humans. This situation could become dramatically worse if the infectivity of avian viruses for humans were increased by reassortment between the genes of human and avian viruses. Co-infection of humans or an intermediate host with an avian strain and an existing human strain could produce new viruses of unknown pathogenicity to which the entire population would be susceptible. Inactivated vaccines against influenza have been prepared for many years using viruses grown in embryonated chicken eggs. However, the use of eggs presents difficulties when vaccine supplies need to be expanded at short notice. It seems likely that future vaccines will be prepared in high-yielding cell cultures from continuous lines that are preferably anchorage-independent. At present, only certain preparations of the Vero and Madin–Darby canine k...
- 1 January 2004
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 4 (5) , 709-717
The role of cell culture vaccines in the control of the next influenza pandemic
Pandemic influenza A viruses of avian origin are of particular concern and have crossed the species barrier several times in recent years, giving rise to illness and occasionally death in humans. This situation could become dramatically worse if the infectivity of avian viruses for humans were increased by reassortment between the genes of human and avian viruses. Co-infection of humans or an intermediate host with an avian strain and an existing human strain could produce new viruses of unknown pathogenicity to which the entire population would be susceptible. Inactivated vaccines against influenza have been prepared for many years using viruses grown in embryonated chicken eggs. However, the use of eggs presents difficulties when vaccine supplies need to be expanded at short notice. It seems likely that future vaccines will be prepared in high-yielding cell cultures from continuous lines that are preferably anchorage-independent. At present, only certain preparations of the Vero and Madin–Darby canine k...
- 11 October 2002
- Published by Elsevier in Journal of Virological Methods
- Vol. 107 (1) , 63-69
An evaluation of the genetic stability and pathogenicity of the Russian cold-adapted influenza A donor strains A/Leningrad/134/17/57 and A/Leningrad/134/47/57 in ferrets
- 11 October 2002
- Published by Elsevier in Journal of Virological Methods
- Vol. 107 (1) , 63-69
An evaluation of the genetic stability and pathogenicity of the Russian cold-adapted influenza A donor strains A/Leningrad/134/17/57 and A/Leningrad/134/47/57 in ferrets